1 Study Matches
A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome
Basal Cell Nevus Syndrome: Phase 3 Double-Blind, 12 month study. Topical Gel, Males/Females 18 years and older with Basal Cell Nevus (Gorlin) syndrome. Basal Cell Carcinomas (BCC) are slow growing tumors of the skin. They can be sporadic or inherited. Basal Cell nevus (Gorlin) syndrome is a rare autosomal dominant heritable disease. The purpose of the study is to assess the number of new surgical BCCs and to evaluate the safety of the drug and how the drug is tolerated in patients.
18 year(s) or older
Inclusion Criteria:Must have had at least 10 (at least 3 on face) Basal Cell Carcinomas present within the past 24 months
Must be willing to have blood collected
Willing to follow all study instructions
Exclusion Criteria:Certain treatments are not allowed; coordinator will discuss specific treatments
unable or unwilling to return to the study site for all study visits and tests.
Certain invasive cancers are not allowed to participate; coordinator will discuss
Skin Conditions, Cancer